Human Organoids Market Trends

Growth Drivers

• Rising Prevalence of Infectious Disease – Human organoids offer a chance to enhance human health in connection to infectious illnesses.  Annual influenza A and B epidemics in the US from 2010 to 2020 caused 9–45 million infections, 140,000–810,000 hospitalizations, and 12,000–61,000 fatalities per year. Moreover, SARS-CoV-2 caused more than 22.3 million reported infections and more than 373,000 fatalities from COVID-19 in the US between January 21, 2020, and January 11, 2021.

• Higher Procedure of Organ Transplantation – Human organoids are helpful in drug testing of transplantation therapy. Compared to the number of available organs, a lot more people need transplants. While 95% of American adults support organ donation, just 54% are actually registered donors.

• Higher Use of Human Genes for Experiment – Human organoids can study human genes for treating major disease, such as cancer, genetic disorders, and others. More than 300 million samples of human tissue are thought to exist in various collections around the globe.

• Increasing Clinical Trials for Regenerative Medicines – Preclinical drug testing of regenerative medicines uses human organoids in biomedical research. There are now more than 1,500 clinical trials including regenerative medicine. Clinical trials for regenerative medicine grew overall between 2005 and 2018, with the highest percentage that is around 10% of studies occurring in 2020.

• Rising Investment in Organoids Development - Investment in organoids study is likely to drive market growth.  Prior to Phase 2a studies, LyGenesis, Inc. has raised USD 4 million, which works as a stepping stone to a larger investment round in 2020.

Challenges

• Inadequate infrastructure for 3D cell culture- The availability of the necessary equipment to use advanced techniques is one of the prerequisites for conducting 3D cell culture-based research. Moreover, deploying the equipment and infrastructure of 3D cell culture is demands huge capital and time.
• Difficulty in incorporating human organoids in previous workflows -
• Low adoption of existing drug discovery